Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Choueiri, TK; Hessel, C; Halabi, S; Sanford, B; Hahn, O; Michaelson, MD; Walsh, M; Olencki, T; Picus, J; Small, EJ; Dakhil, S; Scheffold, C; George, DJ; Morris, MJ

Published Date

  • September 1, 2017

Published In

Volume / Issue

  • 28 /

Published By

Pages

  • 1

Electronic International Standard Serial Number (EISSN)

  • 1569-8041

International Standard Serial Number (ISSN)

  • 0923-7534

Conference Name

  • 42nd European-Society-for-Medical-Oncology Congress (ESMO)

Conference Location

  • Madrid, SPAIN

Conference Start Date

  • September 8, 2017

Conference End Date

  • September 12, 2017